We are initially using the STAR-D platform to develop treatments for rare orphan dermatological indications caused by the absence of or a mutation in a single gene, and plan to leverage our platform to expand our pipeline to include other dermatological indications in the future.

Our lead product candidate, KB103, is currently in preclinical development and seeks to use gene therapy to treat DEB. KB103 is a replication-defective, non-integrating viral vector that has been engineered employing our STAR-D platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells. Other indications in the current pipeline include TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis, and chronic wound healing.

Stage of Development
Product Indication   Research Discovery Preclinical Phase 1/2
KB103 Dystrophic EB Read More Q1 2018
KB105 TGM-1 Deficient ARCI Read More Q4 2018
KB106 Wound Healing Read More